Cargando…
Systematically integrative analysis identifies diagnostic and prognostic candidates and small-molecule drugs for lung adenocarcinoma
BACKGROUND: Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer (LC). However, the early-stage diagnostic rate is still low, and the 5-year overall survival (OS) rate remains poor. The present study aimed to identify critical genes as diagnostic and prognostic markers a...
Autores principales: | Chen, Qiang, Wang, Xiaoyi, Hu, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797894/ https://www.ncbi.nlm.nih.gov/pubmed/35116665 http://dx.doi.org/10.21037/tcr-21-526 |
Ejemplares similares
-
Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
por: Cheng, Yang, et al.
Publicado: (2021) -
Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes
por: Chen, Qiang, et al.
Publicado: (2022) -
Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma
por: Li, Jingyuan, et al.
Publicado: (2020) -
Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma
por: Hu, Jing, et al.
Publicado: (2019) -
Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis
por: Wu, Qiong, et al.
Publicado: (2019)